Who Paid My Doc
Barbara Soltes
Reproductive Endocrinology Chicago, IL Medical Doctor
NPI 1164591301 CMS profile 143344
1725 W. Harrison Street, Suite 739, Chicago, IL 60612
General payments
$25,257
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$32,768
Through program year 2025, Barbara Soltes of Chicago, IL is reported in the CMS Open Payments database as having received $25,257 across 56 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $32,768 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 94th percentile of Reproductive Endocrinology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
6 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $18 | 1 | |
| 2023 | General | $99 | 2 | |
| 2022 | General | $191 | 4 | |
| 2021 | General | $5,913 | 9 | |
| 2020 | General | $6,066 | 8 | |
| 2019 | General | $12,971 | 32 |
Beside peers
- Barbara Soltes
- Reproductive Endocrinology median
- Middle half of Reproductive Endocrinology
- National median
In program year 2025, general payments to Barbara Soltes were reported at $18. Among 986 Reproductive Endocrinology profiles paid that year, the median was $141 and the middle half received between $66 and $285.
Show as a table
| Year | Barbara Soltes | Reproductive Endocrinology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $12,971 | $196 | $77–$425 | $163 |
| 2020 | $6,066 | $81 | $35–$182 | $114 |
| 2021 | $5,913 | $102 | $43–$247 | $132 |
| 2022 | $191 | $139 | $62–$303 | $149 |
| 2023 | $99 | $141 | $65–$285 | $160 |
| 2024 | $0 | $144 | $65–$302 | $164 |
| 2025 | $18 | $141 | $66–$285 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 36 drugsPart D claims
1,679
Drug cost
$116,029
Branded share of claims
29.7%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Ozempic Semaglutide | Brand | 36 | $44,294 | |
| Estring Estradiol | Brand | 32 | $17,053 | |
| Estradiol | Generic | 187 | $15,962 | |
| Synthroid Levothyroxine Sodium | Brand | 229 | $12,449 | |
| Premarin Estrogens, Conjugated | Brand | 15 | $8,070 | |
| Imvexxy Estradiol | Brand | 16 | $3,854 | |
| Levothyroxine Sodium | Generic | 280 | $2,327 | |
| Progesterone Progesterone, Micronized | Brand | 46 | $1,612 | |
| Fenofibrate Fenofibrate Nanocrystallized | Brand | 15 | $869 | |
| Risedronate Sodium | Generic | 26 | $827 |
The 10 drugs with the highest cost, of 36 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 28 billing codesPaid by Medicare
$46,459
Medicare patients
198
Services billed
815
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 55% | |
| Arthritis | 44% | |
| Osteoporosis | 36% | |
| Depression | 21% | |
| Diabetes | 17% | |
| Ischemic heart disease | 16% | |
| Cancer | 14% | |
| Chronic kidney disease | 9% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
56 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Reproductive Endocrinology in Illinois
Eve Feinberg
Reproductive Endocrinology · Chicago, IL
Angeline Beltsos
Reproductive Endocrinology · Chicago, IL
Roohi Najeemuddin
Reproductive Endocrinology · Chicago, IL
Sigal Klipstein
Reproductive Endocrinology · Hoffman Estates, IL
Ilan Tur-Kaspa
Reproductive Endocrinology · Chicago, IL
Vishvanath Karande
Reproductive Endocrinology · Hoffman Estates, IL
Related records
Reproductive Endocrinology in Illinois
Practitioners in the same specialty and state, ranked by reported value.
All Reproductive Endocrinology
Everyone recorded under this specialty, nationwide.
Doctors in Illinois
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.